

(Catalogue of Federal Domestic Assistance Program Nos. 93.879, Medical Library Assistance, National Institutes of Health, HHS)

Dated: October 26, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01-27512 Filed 11-1-01; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications; the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: November 2, 2001.

Time: 1:45 pm to 2:30 pm.

Agenda: To review and evaluate grant applications.

Place: Westin Grand Hotel 2350 M Street, NW., Washington, DC 20037-1417.

Contact Person: Cheryl M. Corsaro, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2204, MSC 7890, Bethesda, MD 20892, 301/435-1045, corsaroc@csr.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine, 93.306; 93.333, Clinical Research, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, National Institutes of Health, HHS)

Dated: October 26, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01-27511 Filed 11-01-01; 8:45 am]

BILLING CODE 4140-1-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Genome Study Section, November 1, 2001, 8:30 AM to November 2, 2001, 2:30 PM, Embassy Square, 2000 N Street, NW., Washington, DC, 20036 which was published in the **Federal Register** on October 19, 2001, 66 FR 53229-53231.

This meeting will be held at the Westin Grand Hotel, 2350 M Street, NW., Washington, DC 20037. The ending time has been changed to 1:45 PM. The meeting is closed to the public.

Dated: October 26, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01-27514 Filed 11-1-01; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, October 31, 2001, 1:30 PM to November 1, 2001, 5 PM, Holiday Inn, 8120 Wisconsin Avenue, Bethesda, MD, 20814 which was published in the **Federal Register** on October 15, 2001, 66 FR 52441-52444.

The meeting will be one day only October 31, 2001, from 1:30 PM to 5 PM. The location remains the same. The meeting is closed to the public.

Dated: October 26, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01-27515 Filed 11-1-01; 8:45 am]

BILLING CODE 4140-1-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services notifies Federal agencies of the laboratories currently certified to meet standards of subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29916, 29925). A similar notice listing all currently certified laboratories will be published during the first week of each month, and updated to include laboratories which subsequently apply for and complete the certification process. If any listed laboratory's certification is totally suspended or revoked, the laboratory will be omitted from updated lists until such time as it is restored to full certification under the Guidelines.

If any laboratory has withdrawn from the National Laboratory Certification Program during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter.

This notice is also available on the internet at the following Web sites: <http://workplace.samhsa.gov>; <http://www.drugfreeworkplace.gov>; and <http://www.health.org/workplace>.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh or Dr. Walter Vogl, Division of Workplace Programs, 5600 Fishers Lane, Rockwall 2 Building, Room 815, Rockville, Maryland 20857; Tel.: (301) 443-6014, Fax: (301) 443-3031.

SUPPLEMENTARY INFORMATION: Mandatory Guidelines for Federal Workplace Drug Testing were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100-71. Subpart C of the Guidelines, "Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies," sets strict standards which laboratories must meet in order to conduct urine drug testing for Federal agencies. To become certified an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection.

To maintain that certification a laboratory must participate in a quarterly performance testing program plus periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements expressed in the HHS Guidelines. A laboratory must have its letter of certification from SAMHSA, HHS (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with subpart C of the Guidelines, the following laboratories meet the minimum standards set forth in the Guidelines:

- ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414-328-7840/800-877-7016 (Formerly: Bayshore Clinical Laboratory)
- ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 716-429-2264
- Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis, TN 38118, 901-794-5770/888-290-1150
- Aegis Analytical Laboratories, Inc., 345 Hill Ave., Nashville, TN 37210, 615-255-2400
- Alliance Laboratory Services, 3200 Burnet Ave., Cincinnati, OH 45229, 513-585-9000 (Formerly: Jewish Hospital of Cincinnati, Inc.)
- American Medical Laboratories, Inc., 14225 Newbrook Dr., Chantilly, VA 20151, 703-802-6900
- Associated Pathologists Laboratories, Inc., 4230 South Burnham Ave., Suite 250, Las Vegas, NV 89119-5412, 702-733-7866/800-433-2750
- Baptist Medical Center—Toxicology Laboratory, 9601 I-630, Exit 7, Little Rock, AR 72205-7299, 501-202-2783 (Formerly: Forensic Toxicology Laboratory Baptist Medical Center)
- Clinical Laboratory Partners, LLC, 129 East Cedar St., Newington, CT 06111, 860-696-8115 (Formerly: Hartford Hospital Toxicology Laboratory)
- Clinical Reference Lab, 8433 Quivira Rd., Lenexa, KS 66215-2802, 800-445-6917
- Cox Health Systems, Department of Toxicology, 1423 North Jefferson Ave., Springfield, MO 65802, 800-876-3652/417-269-3093 (Formerly: Cox Medical Centers)
- Diagnostic Services Inc., dba DSI, 12700 Westlinks Drive, Fort Myers, FL 33913, 941-561-8200/800-735-5416
- Doctors Laboratory, Inc., P.O. Box 2658, 2906 Julia Dr., Valdosta, GA 31602, 912-244-4468
- DrugProof, Division of Dynacare, 543 South Hull St., Montgomery, AL 36103, 888-777-9497/334-241-0522 (Formerly: Alabama Reference Laboratories, Inc.)
- DrugProof, Division of Dynacare/Laboratory of Pathology, LLC, 1229 Madison St., Suite 500, Nordstrom Medical Tower, Seattle, WA 98104, 206-386-2672/800-898-0180 (Formerly: Laboratory of Pathology of Seattle, Inc., DrugProof, Division of Laboratory of Pathology of Seattle, Inc.)
- DrugScan, Inc., P.O. Box 2969, 1119 Mearns Rd., Warminster, PA 18974, 215-674-9310
- Dynacare Kasper Medical Laboratories*, 14940-123 Ave., Edmonton, Alberta, Canada T5V 1B4, 780-451-3702/800-661-9876
- ElSohly Laboratories, Inc., 5 Industrial Park Dr., Oxford, MS 38655, 662-236-2609
- Express Analytical Labs, 1301 18th Ave., NW., Suite 110, Austin, MN 55912, 507-437-7322
- Gamma-Dynacare Medical Laboratories *, A Division of the Gamma-Dynacare Laboratory Partnership, 245 Pall Mall St., London, ONT, Canada N6A 1P4, 519-679-1630
- General Medical Laboratories, 36 South Brooks St., Madison, WI 53715, 608-267-6267
- Kroll Laboratory Specialists, Inc., 1111 Newton St., Gretna, LA 70053, 504-361-8989/800-433-3823 (Formerly: Laboratory Specialists, Inc.)
- LabOne, Inc., 10101 Renner Blvd., Lenexa, KS 66219, 913-888-3927/800-728-4064 (Formerly: Center for Laboratory Services, a Division of LabOne, Inc.)
- Laboratory Corporation of America Holdings, 7207 N. Gessner Road, Houston, TX 77040, 713-856-8288/800-800-2387
- Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 908-526-2400/800-437-4986 (Formerly: Roche Biomedical Laboratories, Inc.)
- Laboratory Corporation of America Holdings, 1904 Alexander Drive, Research Triangle Park, NC 27709, 919-572-6900/800-833-3984 (Formerly: LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group)
- Laboratory Corporation of America Holdings, 10788 Roselle Street, San Diego, CA 92121, 800-882-7272 (Formerly: Poisonlab, Inc.)
- Laboratory Corporation of America Holdings, 1120 Stateline Road West, Southaven, MS 38671, 866-827-8042/800-233-6339 (Formerly: LabCorp Occupational Testing Services, Inc., MedExpress/National Laboratory Center)
- Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North Oak Ave., Marshfield, WI 54449, 715-389-3734/800-331-3734
- MAXXAM Analytics Inc.*, 5540 McAdam Rd., Mississauga, ON, Canada L4Z 1P1, 905-890-2555 (Formerly: NOVAMANN (Ontario) Inc.)
- Medical College Hospitals Toxicology Laboratory, Department of Pathology, 3000 Arlington Ave., Toledo, OH 43699, 419-383-5213
- MedTox Laboratories, Inc., 402 W. County Rd. D, St. Paul, MN 55112, 651-636-7466/800-832-3244
- MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 97232, 503-413-5295/800-950-5295
- Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, Minnesota 55417, 612-725-2088
- National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304, 661-322-4250/800-350-3515
- Northwest Drug Testing, a division of NWT Inc., 1141 E. 3900 South, Salt Lake City, UT 84124, 801-293-2300/800-322-3361 (Formerly: NWT Drug Testing, NorthWest Toxicology, Inc.)
- One Source Toxicology Laboratory, Inc., 1705 Center Street, Deer Park, TX 77536, 713-920-2559 (Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory)
- Oregon Medical Laboratories, P.O. Box 972, 722 East 11th Ave., Eugene, OR 97440-0972, 541-687-2134
- Pacific Toxicology Laboratories, 6160 Variel Ave., Woodland Hills, CA 91367, 818-598-3110/800-328-6942 (Formerly: Centinela Hospital Airport Toxicology Laboratory)
- Pathology Associates Medical Laboratories, 11604 E. Indiana Ave., Spokane, WA 99206, 509-926-2400/800-541-7891
- PharmChem Laboratories, Inc., Texas Division, 7606 Pebble Dr., Fort Worth, TX 76118, 817-215-8800 (Formerly: Harris Medical Laboratory)
- Physicians Reference Laboratory, 7800 West 110th St., Overland Park, KS 66210, 913-339-0372/800-821-3627
- Quest Diagnostics Incorporated, 3175 Presidential Dr., Atlanta, GA 30340, 770-452-1590 (Formerly: SmithKline Beecham Clinical Laboratories, SmithKline Bio-Science Laboratories)
- Quest Diagnostics Incorporated, 4770 Regent Blvd., Irving, TX 75063, 800-842-6152 (Moved from the Dallas location on 03/31/01; Formerly: SmithKline Beecham Clinical Laboratories, SmithKline Bio-Science Laboratories)
- Quest Diagnostics Incorporated, 400 Egypt Rd., Norristown, PA 19403, 610-631-4600/877-642-2216 (Formerly: SmithKline Beecham Clinical Laboratories, SmithKline Bio-Science Laboratories)
- Quest Diagnostics Incorporated, 506 E. State Pkwy., Schaumburg, IL 60173, 800-669-6995/847-885-2010 (Formerly: SmithKline Beecham Clinical Laboratories, International Toxicology Laboratories)
- Quest Diagnostics Incorporated, 7470 Mission Valley Rd., San Diego, CA 92108-4406, 619-686-3200 / 800-446-4728 (Formerly: Nichols Institute, Nichols Institute Substance Abuse Testing (NISAT), CORNING Nichols Institute, CORNING Clinical Laboratories)
- Quest Diagnostics Incorporated, 7600 Tyrone Ave., Van Nuys, CA 91405, 818-989-2520 / 800-877-2520 (Formerly: SmithKline Beecham Clinical Laboratories)
- Scientific Testing Laboratories, Inc., 463 Southlake Blvd., Richmond, VA 23236, 804-378-9130
- S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM 87109, 505-727-6300 / 800-999-5227
- South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South Bend, IN 46601, 219-234-4176
- Southwest Laboratories, 2727 W. Baseline Rd., Tempe, AZ 85283, 602-438-8507 / 800-279-0027
- Sparrow Health System, Toxicology Testing Center, St. Lawrence Campus, 1210 W. Saginaw, Lansing, MI 48915, 517-377-0520 (Formerly: St. Lawrence Hospital & Healthcare System)
- St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St., Oklahoma City, OK 73101, 405-272-7052
- Toxicology & Drug Monitoring Laboratory, University of Missouri Hospital & Clinics,

2703 Clark Lane, Suite B, Lower Level,
Columbia, MO 65202, 573-882-1273
Toxicology Testing Service, Inc., 5426 N.W.
79th Ave., Miami, FL 33166, 305-593-
2260

Universal Toxicology Laboratories (Florida),
LLC, 5361 NW 33rd Avenue, Fort
Lauderdale, FL 33309, 954-717-0300, 800-
522-0232x419 (Formerly: Integrated
Regional Laboratories, Cedars Medical
Center, Department of Pathology)

Universal Toxicology Laboratories, LLC, 9930
W. Highway 80, Midland, TX 79706, 915-
561-8851 / 888-953-8851

US Army Forensic Toxicology Drug Testing
Laboratory, Fort Meade, Building 2490,
Wilson Street, Fort George G. Meade, MD
20755-5235, 301-677-7085

The following laboratories are voluntarily
withdrawing from the NLCP:

Withdrawal effective November 1, 2001:
Dept. of the Navy, Navy Drug Screening
Laboratory, Great Lakes, IL, Building 38-H,
P. O. Box 88-6819, Great Lakes, IL 60088-
6819, 847-688-2045 / 847-688-4171

Withdrawal effective October 1, 2001: Quest
Diagnostics Incorporated, 801 East Dixie
Ave., Suite 105A, Leesburg, FL 34748,
352-787-9006x4343 (Formerly:
SmithKline Beecham Clinical Laboratories,
Doctors & Physicians Laboratory)

Withdrawal effective October 1, 2001: Quest
Diagnostics Incorporated, 4444 Giddings
Road, Auburn Hills, MI 48326, 248-373-
9120 / 800-444-0106 (Formerly:
HealthCare/Preferred Laboratories,
HealthCare/MetPath, CORNING Clinical
Laboratories)

Withdrawal effective October 1, 2001: Quest
Diagnostics Incorporated, One Malcolm
Ave., Teterboro, NJ 07608, 201-393-5590
(Formerly: MetPath, Inc., CORNING
MetPath Clinical Laboratories, CORNING
Clinical Laboratory)

*The Standards Council of Canada (SCC)
voted to end its Laboratory Accreditation
Program for Substance Abuse (LAPSA)
effective May 12, 1998. Laboratories certified
through that program were accredited to
conduct forensic urine drug testing as
required by U.S. Department of
Transportation (DOT) regulations. As of that
date, the certification of those accredited
Canadian laboratories will continue under
DOT authority. The responsibility for
conducting quarterly performance testing
plus periodic on-site inspections of those
LAPSA-accredited laboratories was
transferred to the U.S. DHHS, with the
DHHS' National Laboratory Certification
Program (NLCP) contractor continuing to
have an active role in the performance testing
and laboratory inspection processes. Other
Canadian laboratories wishing to be
considered for the NLCP may apply directly
to the NLCP contractor just as U.S.
laboratories do.

Upon finding a Canadian laboratory to be
qualified, the DHHS will recommend that
DOT certify the laboratory (**Federal Register**,
16 July 1996) as meeting the minimum
standards of the "Mandatory Guidelines for
Workplace Drug Testing" (59 **Federal
Register**, 9 June 1994, Pages 29908-29931).

After receiving the DOT certification, the
laboratory will be included in the monthly
list of DHHS certified laboratories and
participate in the NLCP certification
maintenance program.

Richard Kopanda,

*Executive Officer, Substance Abuse and
Mental Health Services Administration.*

[FR Doc. 01-27530 Filed 11-1-01; 8:45 am]

BILLING CODE 4160-20-U

**DEPARTMENT OF HEALTH AND
HUMAN SERVICES**

**Substance Abuse and Mental Health
Services Administration**

**Notice of Intent To Issue a Notice of
Funding Availability for Cooperative
Agreements for Addiction Technology
Transfer Center (ATTC) Sites and an
ATTC National Office**

AGENCY: Center for Substance Abuse
Treatment (CSAT), Substance Abuse
and Mental Health Services
Administration (SAMHSA), DHHS.

ACTION: Notification of SAMHSA/
CSAT's intent to announce the
availability of FY 2002 funds for
cooperative agreements for seven ATTC
sites and an ATTC National Office.

SUMMARY: This notice is to inform the
public of SAMHSA/CSAT's intention to
issue a Notice of Funding Availability in
late October or early November, to
announce the availability of FY 2002
funds for cooperative agreements to
support 7 ATTC sites to cover 7 ATTC
Regions and an ATTC National Office.
CSAT's ATTC program is comprised of
14 ATTC Regions and an ATTC
National Office that together form a
network which, individually and
collaboratively, provides academic,
continuing education, professional
development and practicum training to
professionals/providers in the substance
abuse treatment field. The ATTC
National Office coordinates all cross-site
and multi-site activities of the 14 ATTC
regions.

In FY 2001, awards were made to sites
to cover 7 of the 14 ATTC Regions. In
FY 2002, it is SAMHSA/CSAT's intent
to solicit applications for an ATTC
National Office and for coverage of the
following currently uncovered 7 ATTC
Regions:

Region 5: Georgia and South Carolina;

Region 7: Puerto Rico and U.S. Virgin

Islands;

Region 8: Missouri, Kansas, Oklahoma, and
Arkansas;

Region 9: Iowa, Nebraska, North Dakota,
South Dakota, and Minnesota;

Region 10: Illinois, Indiana, Ohio, Wisconsin,
and Michigan;

Region 13: California, New Mexico, Arizona,
and Colorado (criminal justice); and
Region 14: Florida and Alabama.

Questions related to CSAT's ATTC
program should be directed to Susanne
Rohrer, RN, Office of Evaluation,
Scientific Analysis, and Synthesis,
CSAT, Rockwall IL, Suite 840, 5600
Fishers Lane, Rockville, MD 20857;
telephone (301) 443-8521; e-mail
srohrer@samhsa.gov.

Dated: October 28, 2001.

Richard Kopanda,

Executive Officer, SAMHSA.

[FR Doc. 01-27521 Filed 11-1-01; 8:45 am]

BILLING CODE 4162-20-P

**DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT**

[Docket No. FR-4650-N-81]

**Notice of Submission of Proposed
Information Collection to OMB;
Revision of Cost Limits for Native
American Housing**

AGENCY: Office of the Chief Information
Officer, HUD.

ACTION: Notice.

SUMMARY: The proposed information
collection requirement described below
has been submitted to the Office of
Management and Budget (OMB) for
review, as required by the Paperwork
Reduction Act. The Department is
soliciting public comments on the
subject proposal.

DATES: *Comments Due Date:* December
3, 2001.

ADDRESSES: Interested persons are
invited to submit comments regarding
this proposal. Comments should refer to
the proposal by name and/or OMB
approval number and should be sent to:
Joseph F. Lackey Jr., OMB Desk Officer,
Office of Management and Budget,
Room 10235, New Executive Office
Building, Washington, DC 20503.

FOR FURTHER INFORMATION CONTACT:
Wayne Eddins, Reports Management
Office, Q, Department of Housing and
Urban Development, 451 Seventh Street,
Southwest, Washington, DC 20410; e-
mail: Wayne_Eddins@HUD.gov;
telephone (202) 708-2374. This is not a
toll-free number. Copies of the proposed
forms and other available documents
submitted to OMB may be obtained
from Mr. Eddins.

SUPPLEMENTARY INFORMATION: The
Department has submitted the proposal
for the collection of information, as
described below, to OMB for review, as
required by the Paperwork Reduction
Act (44 U.S.C. Chapter 350). The Notice